Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Perseus Proteomics's share price for the quarter that ended in Mar. 2026 was 円220. Perseus Proteomics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 17.0 Mil. Therefore, Perseus Proteomics's market cap for the quarter that ended in Mar. 2026 was 円3,740.0 Mil.
Perseus Proteomics's quarterly market cap
declined
from Mar. 2025 (円10,855.3 Mil) to Sep. 2025 (円4,719.7 Mil) and
declined
from Sep. 2025 (円4,719.7 Mil) to Mar. 2026 (円3,740.0 Mil).
Perseus Proteomics's annual market cap
increased
from Mar. 2024 (円4,010.5 Mil) to Mar. 2025 (円10,855.3 Mil) but then
declined
from Mar. 2025 (円10,855.3 Mil) to Mar. 2026 (円3,740.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Perseus Proteomics's Enterprise Value for Today is 円1,204.6 Mil.
Perseus Proteomics (TSE:4882) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Perseus Proteomics Market Cap Related Terms
Perseus Proteomics Market Cap Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Market Cap distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Perseus Proteomics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a Market Cap of 円2,719.9 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Perseus Proteomics and its competitors. According to the industry distribution chart, Perseus Proteomics ranks #827 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Perseus Proteomics' Market Cap too high?
Perseus Proteomics' current Market Cap is 円2,719.9 Mil. Based on the distribution chart, Perseus Proteomics ranks #827 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #827 out of 1024 companies for Market Cap. This places Perseus Proteomics in the lower half of its industry. The industry median Market Cap is 219.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 219.58, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 219.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Market Cap is 円2,719.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Market Cap is 円2,719.9 Mil. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Market Cap is 円2,719.9 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Market Cap: 円2,719.9 Mil
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
